Low-Dose Peginterferon Alfa-2a Is Safe and Produces a Sustained Virologic Response in Patients With Chronic Hepatitis C and End-Stage Renal Disease
Tarih
2011Yazar
Messinger, Diethelm
Besisik, Fatih
Cheinquer, Hugo
Samuel, Didier
Tietz, Andreas
Peck-Radosavljevic, Markus
Boletis, John
Ferraz, Maria Lucia
Alric, Laurent
Üst veri
Tüm öğe kaydını gösterÖzet
BACKGROUND & AIMS: Chronic hepatitis C increases mortality of patients with end-stage renal disease (ESRD). Ribavirin is not recommended for patients with renal dysfunction; peginterferon monotherapy is the most appropriate treatment for chronic hepatitis C in such patients. We evaluated the efficacy and safety of 2 dosages of peginterferon alfa-2a (40 kDa) in patients with chronic hepatitis C and ESRD on hemodialysis. METHODS: We performed a randomized, multicenter, open-label clinical study of 85 patients with chronic hepatitis C and ESRD who were receiving hemodialysis at specialist outpatient hepatology clinics. Patients were treated with subcutaneous peginterferon alfa-2a (40 kDa) at dosages of 135 or 90 mu g/wk for 48 weeks. RESULTS: The incidences of overall sustained virologic responses (SVRs) (undetectable hepatitis C virus [HCV] RNA [ 10% of patients in at least 1 treatment group) included conditions associated with ESRD (anemia and hypertension) and with interferon treatment. CONCLUSIONS: Forty-eight weeks of treatment with low-dose peginterferon alfa-2a (40 kDa) is safe and produces an SVR in 35%-40% of patients with chronic hepatitis C and ESRD on hemodialysis.
Bağlantı
http://hdl.handle.net/20.500.12627/34320https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79951699393&origin=inward
https://doi.org/10.1016/j.cgh.2010.10.018
Koleksiyonlar
- Makale [92796]